Dermapharm Holding SE Cash Flow-to-Debt Ratio
Dermapharm Holding SE cash flow-to-debt ratio. Dermapharm Holding SE (DMP) has a Cash Flow-to-Debt Ratio of 0.03x as of March 2026, meaning its operating cash flow of €39.49 Million could theoretically repay 0% of its total liabilities (€1.54 Billion) in one year. Check how high is Dermapharm Holding SE's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Dermapharm Holding SE (2014–2025)
Cash flow-to-debt ratio of Dermapharm Holding SE from 2014 to 2025. Historical debt coverage capacity for Dermapharm Holding SE across 12 annual periods. Check total reinvestment intensity of Dermapharm Holding SE to assess the company's total reinvestment commitment from operating cash flow.
Dermapharm Holding SE Cash Flow-to-Debt Ratio by Year (2014–2025)
Dermapharm Holding SE cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for Dermapharm Holding SE. For the full cash flow conversion analysis, see Dermapharm Holding SE cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.12x | €181.51 Million | €1.50 Billion | ▼ -11.7% |
| 2024 | 0.14x | €201.38 Million | €1.47 Billion | ▲ +0.8% |
| 2023 | 0.14x | €219.42 Million | €1.62 Billion | ▼ -58.6% |
| 2022 | 0.33x | €288.53 Million | €880.34 Million | ▲ +18.8% |
| 2021 | 0.28x | €250.37 Million | €907.13 Million | ▲ +89.4% |
| 2020 | 0.15x | €131.10 Million | €899.81 Million | ▲ +10.1% |
| 2019 | 0.13x | €100.61 Million | €760.38 Million | ▼ -62.7% |
| 2018 | 0.35x | €159.13 Million | €448.50 Million | ▲ +39.7% |
| 2017 | 0.25x | €86.74 Million | €341.62 Million | ▼ -17.0% |
| 2016 | 0.31x | €76.78 Million | €250.89 Million | ▲ +91.2% |
| 2015 | 0.16x | €40.38 Million | €252.22 Million | ▼ -12.5% |
| 2014 | 0.18x | €54.26 Million | €296.59 Million | — |